Device Trial Radar · NCT05796453
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
470
Actual
Start
Sep 19, 2023
Primary completion
Aug 21, 2026
Study completion Aug 21, 2026
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.
Conditions
- Aphakia
- Astigmatism
- Presbyopia
Interventions
Clareon Vivity IOL - Non ToricDevice
Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
Clareon Vivity IOL - ToricDevice
Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
Clareon PanOptix Trifocal IOL - Non ToricDevice
Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
Clareon PanOptix Trifocal IOL - ToricDevice
Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) at each prospective visitTime frame: Up to Year 3
- Number of Adverse EventsTime frame: Up to Year 3
- Number of Device DeficienciesTime frame: Up to Year 3
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Wolstan & Goldberg Eye Associates
Torrance, California
Levenson Eye Associates
Jacksonville, Florida
Eye Surgeons of CNY
Liverpool, New York
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.